Savara Inc
SVRAHealthcare|Biotechnology|USA
$6.03
-0.26 (-4.06%)
Tangible Book
$0.80
Earnings Power
$0.88
Upcoming Data Readouts (1)
Jun 2027
Est. completion
P3Autoimmune Pulmonary Alveolar Proteinosis
Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
NCT06431776n=5
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
Nov 2023
P3
Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
NCT04544293